Asia Vets Holdings (Catalist:5RE) Full Year 2023 Results

Key Financial Results

• Revenue: S$2.33m (down 3.9% from FY 2022).

• Net loss: S$744.3k (loss narrowed by 3.0% from FY 2022).

• S$0.005 loss per share (in line with FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Provision of Veterinary Services and Sales of Veterinary Medicines and Products contributing S$2.33m. Notably, cost of sales worth S$1.63m amounted to 70% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to S$1.48m (103% of total expenses). Explore how 5RE's revenue and expenses shape its earnings.

Asia Vets Holdings' share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Asia Vets Holdings you should be aware of, and 2 of them are concerning.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.